{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006586","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.524807+00:00","generated_at":"2026-06-18T08:38:47.982522+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TScan Therapeutics reports Q4 net loss of $18.7M; cash $120M funds operations into Q2 2024","bullets":["Q4 2022 net loss $18.7M vs $14.2M in Q4 2021; FY2022 net loss $66.2M vs $48.6M.","Q4 2022 revenue $3.1M, up from $2.9M; FY2022 revenue $13.5M (vs $10.1M in 2021).","Cash and cash equivalents $120.0M as of Dec. 31, 2022; runway into Q2 2024.","Phase 1 hematologic trial for TSC-100/101 expected to enroll all three arms by mid-2023 with preliminary safety/biomarker data.","Solid tumor INDs for T-Plex and two TCRs cleared; initial single-agent TCR data expected by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006586","json":"https://secwatch.observer/filing/0000950170-23-006586.json","markdown":"https://secwatch.observer/filing/0000950170-23-006586.md","text":"https://secwatch.observer/filing/0000950170-23-006586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023006586/0000950170-23-006586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023006586/tcrx-20230308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:38:47.982522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"307f2b3041d5bd781baec7f1f3d425fb88183f34","claim":"TScan Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On March 8, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023006586/0000950170-23-006586-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}